Extended autoantibody panel in Turkish patients with early-stage systemic sclerosis: Coexpressions and their influences on clinical phenotypes.
autoantibody
immunoblot assay
indirect immunofluorescence assay
scleroderma-specific antibodies
systemic sclerosis
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
01
08
2023
received:
15
05
2023
accepted:
05
11
2023
medline:
22
12
2023
pubmed:
22
12
2023
entrez:
22
12
2023
Statut:
ppublish
Résumé
To investigate the frequency and clinical relevance of an extended autoantibody profile in patients with systemic sclerosis (SSc). In this cross-sectional study, serum from 100 consecutive patients was subjected to indirect immunofluorescence (IIF) (HEp-20-10/primate liver mosaic) and Systemic Sclerosis Profile by EUROIMMUN to evaluate anti-nuclear antibodies (ANA) and autoantibodies against 13 different autoantibodies in patients with SSc less than 3 years. Ninety-three of 100 patients were positive for ANA by IIF. Fifty-three patients showed single positivity, 26 anti-topoisomerase antibodies (anti-Scl70 ab), 16 anticentromere antibodies (ACAs), six anti-RNA polymerase III antibodies (anti-RNAPIII ab), one anti-Ku antibody, one anti-PM/Scl100 antibody, two anti-PM/Scl75 antibodies, one anti-Ro52 antibody, whereas 32 patients had multiple autoantibody positivities. Among classic SSc-specific autoantibodies, anti-Scl70 and anti-RNAPIII abs showed the highest cooccurrence (n = 4). One patient was simultaneously positive for anti-RNAPIII ab and ACA, and one was positive for ACA and anti-Scl70 ab. The clinical features were not statistically different between single and multiple autoantibody-positivity for classic SSc-specific autoantibodies (ACA, anti-Scl70 ab, and anti-RNAPIII ab), except for digital ulcer in the multiantibody positive ACA group (p = .019). Based on our results, coexpression of autoantibodies is not uncommon in SSc patients. Although autoantibodies specific to SSc in early disease show generally known clinical features, it remains to be investigated how the coexpression of autoantibodies will affect clinical presentation.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
To investigate the frequency and clinical relevance of an extended autoantibody profile in patients with systemic sclerosis (SSc).
MATERIALS AND METHODS
METHODS
In this cross-sectional study, serum from 100 consecutive patients was subjected to indirect immunofluorescence (IIF) (HEp-20-10/primate liver mosaic) and Systemic Sclerosis Profile by EUROIMMUN to evaluate anti-nuclear antibodies (ANA) and autoantibodies against 13 different autoantibodies in patients with SSc less than 3 years.
RESULTS
RESULTS
Ninety-three of 100 patients were positive for ANA by IIF. Fifty-three patients showed single positivity, 26 anti-topoisomerase antibodies (anti-Scl70 ab), 16 anticentromere antibodies (ACAs), six anti-RNA polymerase III antibodies (anti-RNAPIII ab), one anti-Ku antibody, one anti-PM/Scl100 antibody, two anti-PM/Scl75 antibodies, one anti-Ro52 antibody, whereas 32 patients had multiple autoantibody positivities. Among classic SSc-specific autoantibodies, anti-Scl70 and anti-RNAPIII abs showed the highest cooccurrence (n = 4). One patient was simultaneously positive for anti-RNAPIII ab and ACA, and one was positive for ACA and anti-Scl70 ab. The clinical features were not statistically different between single and multiple autoantibody-positivity for classic SSc-specific autoantibodies (ACA, anti-Scl70 ab, and anti-RNAPIII ab), except for digital ulcer in the multiantibody positive ACA group (p = .019).
CONCLUSION
CONCLUSIONS
Based on our results, coexpression of autoantibodies is not uncommon in SSc patients. Although autoantibodies specific to SSc in early disease show generally known clinical features, it remains to be investigated how the coexpression of autoantibodies will affect clinical presentation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1089Informations de copyright
© 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Rel Dis. 2017;2(3):137e52.
Stochmal A, Czuwara J, Trojanowska M, Rudnicka L. Anti-nuclear antibodies in systemic sclerosis: an update. Clin Rev Allergy Immunol. 2020;58(1):40-51.
Patterson KA, Roberts-Thomson PJ, Lester S, et al. Interpretation of an extended autoantibody profile in a well-characterized australian systemic sclerosis (scleroderma) cohort using principal components analysis. Arthritis Rheumatol. 2015;67(12):3234-3244. doi:10.1002/art.39316
Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12(3):340-354.
Kayser C, Fritzler MJ. Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol. 2015;6:1-6.
LeRoy EC, Medsger, Jr. TA. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573-1576.
Avouac J, Fransen J, Walker U, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR scleroderma trials and research group. Ann Rheum Dis. 2011;70(3):476-481. doi:10.1136/ard.2010.136929
Domsic RT. Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement. Curr Opin Rheumatol. 2014;26:646-652.
Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747-1755.
LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202-205.
Nihtyanova SI, Sari A, Harvey JC, et al. Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis Rheumatol. 2020;72(3):465-476. doi:10.1002/art.41153
Mierau R, Moinzadeh P, Riemekasten G, et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Res Ther. 2011;13(5):R172.
Liaskos C, Marou E, Simopoulou T, et al. Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity. 2017;50(7):414-421. doi:10.1080/08916934.2017.1357699
Didier K, Bolko L, Giusti D, et al. Auto-antibodies associated with connective tissue diseases: what meaning for clinicians? Front Immunol. 2018;9:541. doi:10.3389/fimmu.2018.00541
Medsger Jr. TA. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheumatic Dis Clin North Am. 2003;29(2):255-273. doi:10.1016/s0889-857x(03)00023-1
Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281-1285.
Hsu VM, Moreyra AE, Wilson AC, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol. 2008;35:458-465.
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022;61:2200879. doi:10.1183/13993003.00879-2022
Mouthon L, Bussone G, Berezné A, Noël LH, Guillevin L. Scleroderma renal crisis. J Rheumatol. 2014;41(6):1040-1048. doi:10.3899/jrheum.131210
Inanc M, Birlik M, Onat M, et al. The database for systemic sclerosis in Turkey (sys-watch): clinical features, disease activity, severity and functional impairment of 900 patients. Ann Rheumatic Dis. 2009;68(suppl 3):610.
Meyer O. Prognostic markers for systemic sclerosis. Joint Bone Spine. 2006;73(5):490-494. doi:10.1016/j.jbspin.2006.01.022
Choi MY, Fritzler MJ. Progress in understanding the diagnostic and pathogenic role of autoantibodies associated with systemic sclerosis. Curr Opin Rheumatol. 2016;28(6):586-594. doi:10.1097/BOR.0000000000000325
Sibanda EN, Dube Y, Chakawa M, Mduluza T, Mutapi F. Systemic sclerosis in Zimbabwe: autoantibody biomarkers, clinical, and laboratory correlates. Front Immunol. 2021;12:679531. doi:10.3389/fimmu.2021.679531
Yayla ME, İlgen U, Düzgün N. An analysis of the relationship between autoantibodies and clinical findings in patients with systemic sclerosis. Turk J Med Sci. 2018;48(1):10-15. doi:10.3906/sag-1708-67
Nandiwada SL, Peterson LK, Mayes MD, et al. Ethnic differences in autoantibody diversity and hierarchy: more clues from a US cohort of patients with systemic sclerosis. J Rheumatol. 2016;43:1816-1824. doi:10.3899/jrheum.160106
Graf SW, Hakendorf P, Lester S, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheumatic Dis. 2012;15:102-109.
Tan EM. Anti-nuclear antibodies in scleroderma. Int J Dermatol. 1981;20:569-573.
Nakamura RM, Tan EM. Recent advances in laboratory tests and the significance of autoantibodies to nuclear antigens in systemic rheumatic diseases. Clin Lab Med. 1986;6:41-53.
Satoh T, Ishikawa O, Ihn H, et al. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology. 2009;48(12):1570-1574. doi:10.1093/rheumatology/kep290
Miziołek B, Sieńczyk M, Grzywa R, et al. The prevalence and role of functional autoantibodies to angiotensin-converting-enzyme-2 in patients with systemic sclerosis. Autoimmunity. 2021;54(4):181-186. doi:10.1080/08916934.2021.1916915
Cruvinel WM, Andrade LEC, Dellavance A, et al. VI Brazilian consensus guidelines for detection of anti-cell autoantibodies on HEp-2 cells. Adv Rheumatol. 2022;62(1):34. doi:10.1186/s42358-022-00266-z
Lee AYS. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity. Rheumatol Int. 2017;37(8):1323-1333. doi:10.1007/s00296-017-3718-1
Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res. 2014;2014:1-18. doi:10.1155/2014/315179
Hudson M, Pope J, Mahler M, et al. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther. 2012;14(2):R50. doi:10.1186/ar3763
Hudson M, Ghossein C, Steen V. Scleroderma renal crisis. La Presse Médicale’. 2021;50(1):104063. doi:10.1016/j.lpm.2021.104063
Wodkowski M, Hudson M, Proudman S, et al. Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. Autoimmunity. 2015;48(8):542-551. doi:10.3109/08916934.2015.1077231
Koschik II, RW, Fertig N, Lucas MR, et al. Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol. 2012;30(2 Suppl 71):12-16.
Mahler M, Gascon C, Patel S, et al. Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay. Arthritis Res Ther. 2013;15(2):R50. doi:10.1186/ar4210